Understanding and preventing HLA-associated drug reactions

了解和预防 HLA 相关药物反应

基本信息

  • 批准号:
    8934766
  • 负责人:
  • 金额:
    $ 62.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
    至 2016-04-29
  • 项目状态:
    已结题

项目摘要

Understanding and preventing HLA-associated drug reactions Immunologically-mediated adverse drug reactions (IM-ADRs) contribute disproportionately to drug- related morbidity and mortality and the cost and uncertainty of drug development. T-cell mediated drug hypersensitivity reactions are a subset of IM-ADEs that are severe and life-threatening, causing severe skin disease such as Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN), and organ failure. Severe T-cell mediated drug hypersensitivity syndromes have recently been associated with specific class I and/or II HLA alleles which has led to translational pathways for screening and prevention as well as great insight into their immunopathogenesis. The best example is the current widespread use of the HLA class I allele HLA- B*57:01 as a screening test prior to abacavir prescription in routine HIV clinical practice. We have made significant progress in defining the mechanistic basis of the predisposition of HLA-B*57:01 carriers to abacavir hypersensitivity which now has created a translational roadmap to define further the immunopathogenetic mechanisms of other severe HLA-associated T-cell mediated drug hypersensitivity syndromes. Notably, this recent work based on the abacavir model suggests that drugs rapidly and non-covalently bind to an HLA allele and alter the repertoire of self-peptides binding to the allele, creating a vigorous CD8+ T cell response. Abacavir specific CD8+ T-cell responses can be reproduced in-vitro in 100% of HLA-B*57:01 positive abacavir- naïve healthy donors. A key question central to the mechanism of HLA-associated IM-ADRs, and not explained by the altered peptide repertoire model, is why in vivo hypersensitivity generally occurs in only a small proportion of those carrying an HLA-risk allele and what determines the organ specificity of the hypersensitivity. This understanding is integral to the development of prediction and prevention models for severe T-cell mediated drug hypersensitivity. We will address this fundamental question through parallel studies of the T-cell receptor (TCR) usage and the T-cell antigen specificities of the relevant T cells. In Specific Aim 1 we will identify the primary TCR used by T cells in precisely phenotyped drug hypersensitive patients but not HLA-matched drug tolerant controls. We will then define in Specific Aim 2 anti-viral T cells directed against chronic prevalent human herpes viruses (HHV) present in these drug hypersensitive patients but not HLA-risk allele matched drug-tolerants and will focus on stored cell samples from HLA-B*57:01 positive abacavir hypersensitive and HLA-B*15:02 positive SJS/TEN patients. Finally in Specific Aim 3 to test the heterologous immune model, we will identify anti-viral T cells in drug hypersensitive patients that cross- recognize drug in the context of the defined HLA risk allele. The results of these studies will inform strategies for the prediction of severe HLA-associated IM-ADRs and guide drug development and design.
了解和预防HLA相关的药物反应 免疫介导的药物不良反应(IM-ADR)对药物- 相关的发病率和死亡率以及药物开发的成本和不确定性。T细胞介导药物 超敏反应是IM-ADE的一个子集,严重且危及生命,可导致严重的皮肤 疾病如Stevens-Johnson综合征/中毒性表皮坏死松解症(SJS/TEN)和器官衰竭。严重 T细胞介导的药物超敏反应综合征最近与特定的I类和/或II类 HLA等位基因,这导致了翻译途径的筛选和预防,以及伟大的洞察, 它们的免疫发病机制。最好的例子是目前广泛使用的HLA I类等位基因HLA- B*57:01作为常规HIV临床实践中阿巴卡韦处方前的筛查试验。我们取得了 在确定HLA-B*57:01携带者对阿巴卡韦易感性的机制基础方面取得了重大进展 超敏反应,现在已经创建了一个翻译路线图,以进一步定义免疫病理 其他严重HLA相关T细胞介导的药物超敏反应综合征的机制。值得注意的是, 基于阿巴卡韦模型的最新研究表明,药物可以快速地与HLA等位基因非共价结合 并改变与等位基因结合的自身肽库,产生强烈的CD 8 + T细胞反应。 阿巴卡韦特异性CD 8 + T细胞应答可以在100%的HLA-B*57:01阳性阿巴卡韦中体外重现。 天真健康的捐赠者HLA相关IM-ADR机制的一个关键问题, 由改变的肽库模型解释,是为什么体内超敏反应通常只发生在 一小部分携带HLA风险等位基因的人,以及决定器官特异性的因素, 超敏反应这一认识是发展预测和预防模式不可或缺的, 严重的T细胞介导的药物超敏反应。我们将通过平行的方式解决这一基本问题, T细胞受体(TCR)使用和相关T细胞的T细胞抗原特异性的研究。在 具体目标1我们将鉴定T细胞在精确表型的药物过敏中使用的主要TCR。 患者,而不是HLA匹配的药物耐受对照。然后,我们将在特异性目标2中定义抗病毒T细胞 针对这些药物过敏患者中存在的慢性流行人类疱疹病毒(HHV) 但不包括HLA风险等位基因匹配的药物耐受者,并将重点关注来自HLA-B*57:01阳性的储存细胞样本 阿巴卡韦过敏和HLA-B*15:02阳性SJS/TEN患者。最后,在具体目标3中, 异源免疫模型,我们将确定抗病毒T细胞在药物过敏的患者, 在定义的HLA风险等位基因的背景下识别药物。这些研究的结果将为战略提供信息, 用于预测严重的HLA相关IM-ADR并指导药物开发和设计。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elizabeth Phillips其他文献

Elizabeth Phillips的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elizabeth Phillips', 18)}}的其他基金

Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) 2023
史蒂文斯约翰逊综合症/中毒性表皮坏死松解症 (SJS/TEN) 2023
  • 批准号:
    10682795
  • 财政年份:
    2023
  • 资助金额:
    $ 62.55万
  • 项目类别:
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
NATIENS:一项 III 期随机双盲研究,以确定史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的机制和最佳治疗
  • 批准号:
    10217036
  • 财政年份:
    2020
  • 资助金额:
    $ 62.55万
  • 项目类别:
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
NATIENS:一项 III 期随机双盲研究,以确定史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的机制和最佳治疗
  • 批准号:
    10402818
  • 财政年份:
    2020
  • 资助金额:
    $ 62.55万
  • 项目类别:
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
NATIENS:一项 III 期随机双盲研究,以确定史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的机制和最佳治疗
  • 批准号:
    10612063
  • 财政年份:
    2020
  • 资助金额:
    $ 62.55万
  • 项目类别:
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors
幸存者中药物引起的史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症相关的遗传风险和长期结果
  • 批准号:
    10214660
  • 财政年份:
    2019
  • 资助金额:
    $ 62.55万
  • 项目类别:
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors
幸存者中药物引起的史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症相关的遗传风险和长期结果
  • 批准号:
    10441271
  • 财政年份:
    2019
  • 资助金额:
    $ 62.55万
  • 项目类别:
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors
幸存者中药物引起的史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症相关的遗传风险和长期结果
  • 批准号:
    10018069
  • 财政年份:
    2019
  • 资助金额:
    $ 62.55万
  • 项目类别:
Single Cell definition of pathogenic T cells in Drug-induced Stevens-Johnson-Syndrome/Toxic epidermal necrolysis
药物诱导史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症中致病性 T 细胞的单细胞定义
  • 批准号:
    9574331
  • 财政年份:
    2018
  • 资助金额:
    $ 62.55万
  • 项目类别:
Stevens-Johnson Syndrome/Toxic Epidural Necrolysis 2017: Building Multidisciplinary Networks to Drive Science and Translation
史蒂文斯-约翰逊综合症/中毒性硬膜外坏死松解术 2017:建立多学科网络以推动科学和翻译
  • 批准号:
    9261224
  • 财政年份:
    2017
  • 资助金额:
    $ 62.55万
  • 项目类别:
Understanding and preventing HLA-associated drug reactions
了解和预防 HLA 相关药物反应
  • 批准号:
    9100798
  • 财政年份:
  • 资助金额:
    $ 62.55万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 62.55万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.55万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 62.55万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.55万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 62.55万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 62.55万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.55万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 62.55万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 62.55万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.55万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了